The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Open accessAbstract
BACKGROUND: IL-23 expression is increased in psoriatic lesions and might regulate TH17 T-cell counts in patients with psoriasis. OBJECTIVES: We sought to test a novel IL-23-specific therapeutic agent for the treatment of psoriasis. METHODS: In this randomized, double-blind, placebo-controlled study the safety, tolerability, and clinical response of guselkumab, an anti-IL-23-specific mAb, were evaluated in patients with moderate-to-severe plaque psoriasis. A total of 24 patients were randomized to receive a single dose of placebo or 10, 30, 100, or 300 mg of guselkumab. Clinical response was assessed by using the Psoriasis Area and Severity Index (PASI). Additionally, histologic analysis and gene expression in skin biopsy specimens from guselkumab-treated patients were compared with those from placebo-treated patients. RESULTS: At week 12, 50% (10 mg), 60% (30 and 100 mg), and 100% (300 mg) of guselkumab-treated patients, respectively, achieved a 75% improvement in PASI scores from baseline compared with 0% of placebo-treated patients. Improvements in PASI scores were generally maintained through week 24 in all guselkumab-treated patients. The proportion of patients experiencing an adverse event was comparable between the combined guselkumab (13/20 [65.0%]) and placebo (2/4 [50.0%]) groups through week 24. Analysis of lesional and nonlesional skin biopsy specimens demonstrated decreases in epidermal thickness and T-cell and dendritic cell expression in guselkumab-treated patients compared with values seen in placebo-treated patients. At week 12, significant reductions in psoriasis gene expression and serum IL-17A levels were observed in guselkumab-treated patients. CONCLUSION: IL-23 inhibition with a single dose of guselkumab results in clinical responses in patients with moderate-to-severe psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Self-citationA Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
for the Collaborative Association Study of Psoriasis, Nair, R. P., Duffin, K. C., Helms, C., Ding, J., Stuart, P. E., Goldgar, D., Gudjonsson, J. E., Li, Y., Tejasvi, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.311 · Cited by 1,409
Regulation of JAK–STAT signalling in the immune system
Shuai, K., & Liu, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1226 · Cited by 1,372
Cargill, M., Schrodi, S. J., Chang, M., Garcia, V. E., Brandon, R., Callis, K. P., Matsunami, N., Ardlie, K. G., Civello, D., Catanese, J. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/511051 · Cited by 1,086
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Self-citationBrodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Self-citationAnti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Self-citationMast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Lee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., & Krueger, J. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030451 · Cited by 899
Self-citationHueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Chan, J. R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S., Lucian, L., Geissler, R., Brodie, S., Kimball, A. B., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060244 · Cited by 680
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
Zaba, L. C., Cardinale, I., Gilleaudeau, P., Sullivan-Whalen, M., Suárez-Fariñas, M., Fuentes-Duculan, J., Novitskaya, I., Khatcherian, A., Bluth, M. J., Lowes, M. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071094 · Cited by 676
Self-citationCirculating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., & Blauvelt, A. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.399 · Cited by 640
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Self-citationPsoriasis pathophysiology: current concepts of pathogenesis
Krueger, J. G., & Bowcock, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031120 · Cited by 523
Self-citationKryczek, I., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Aphale, A., Vatan, L., Szeliga, W., Wang, Y., Liu, Y., Welling, T. H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4733 · Cited by 470
Self-citationPiskin, G., Sylva-Steenland, R. M. R., Bos, J. D., & Teunissen, M. B. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1908 · Cited by 454
Zaba, L. C., Fuentes-Duculan, J., Eungdamrong, N. J., Abello, M. V., Novitskaya, I., Pierson, K. C., Gonzalez, J., Krueger, J. G., & Lowes, M. A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.194 · Cited by 442
Self-citationPapp, K. A., Griffiths, C. E. M., Gordon, K., Lebwohl, M., Szapary, P. O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P. D., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12214 · Cited by 415
Self-citationIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Krueger, J. G., Fretzin, S., Suárez-Fariñas, M., Haslett, P. A., Phipps, K. M., Cameron, G. S., McColm, J., Katcherian, A., Cueto, I., White, T., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.024 · Cited by 383
Self-citationSuárez-Fariñas, M., Li, K., Fuentes-Duculan, J., Hayden, K., Brodmerkel, C., & Krueger, J. G. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.184 · Cited by 305
Self-citationCutting Edge: Identification of a Motile IL-17–Producing γδ T Cell Population in the Dermis
Gray, E. E., Suzuki, K., & Cyster, J. G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100427 · Cited by 263
Di Meglio, P., Di Cesare, A., Laggner, U., Chu, C.-C., Napolitano, L., Villanova, F., Tosi, I., Capon, F., Trembath, R. C., Peris, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017160 · Cited by 262
Zhang, L., Yang, X.-Q., Cheng, J., Hui, R.-S., & Gao, T.-W. (2010) · Clinical Immunology · doi:10.1016/j.clim.2009.11.008 · Cited by 211
New Insights in the Immunologic Basis of Psoriasis
Nograles, K. E., Davidovici, B., & Krueger, J. G. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.03.001 · Cited by 196
Self-citationHueber, W., Patel, D. D., Dryja, T. P., Wright, A., Bruin, G. J. M., Antoni, C., Gold, M. H., Durez, P., Tak, P. P., Go, J. J., et al. (2010) · Cited by 151
Yawalkar, N., Tscharner, G. G., Hunger, R. E., & Hassan, A. S. (2009) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.01.003 · Cited by 115
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1609337 · Cited by 1,296
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
Self-citationJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationGossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landewé, R., Oliver, S., Aletaha, D., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208337 · Cited by 920
Metadata
- Authors
- Sofen, H., Smith, S., Matheson, R. T., Leonardi, C. L., Calderon, C., Brodmerkel, C., Li, K., Campbell, K., Marciniak, S. J., Wasfi, Y., Wang, Y., Szapary, P., & Krueger, J. G.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 133
- Issue
- 4
- Pages
- 1032-1040
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2003425690
- Cited by
- 320
- References
- 30
- FWCI
- 16.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.